File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Health-Related Quality of Life (HRQL) in East Asian Patients with Hepatitis C Virus (HCV) Infection: The Impact of Treatment and Sustained Virologic Response (SVR)

TitleHealth-Related Quality of Life (HRQL) in East Asian Patients with Hepatitis C Virus (HCV) Infection: The Impact of Treatment and Sustained Virologic Response (SVR)
Authors
Issue Date2017
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The 68th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2017, Washington DC, USA, 20-24 October 2017. In Hepatology, 2017, v. 66 n. Suppl. 1, p. 395A-396A, abstract no. 737 How to Cite?
AbstractBackground: HCV cure leads to HRQL improvement. East Asian (EA) HCV patients have been underrepresented in HRQL studies. Aim: Assess HRQL in EA HCV patients treated with anti-HCV regimens. Methods: EA HCV patients completed Short Form-36 (SF-36) before, during and after treatment and HRQL scores were compared between regimens. Results: 686 EA HCV subjects were included [China: 56.7%, S. Korea: 18.8%, Taiwan: 12.7%, Vietnam: 7.3% and Hong Kong: 4.5%; Genotype (GT) 2: 40.8%, GT1: 29.6%, GT3: 18.4%, GT6: 11.2%; cirrhosis: 13.4%, treatment naïve: 66%]. Patients received pegylated interferon, sofosbuvir and ribavirin (IFN+SOF+RBV) for 12 weeks (n=155, GT 1 and 6) or SOF+RBV for 12-24 weeks (n=531, GT 1, 2, 3 and 6). The SVR-12 was 95.5% and 96.0% (p=0.76). Baseline HRQL scores were similar between treatment groups (all p>0.05). After 2 weeks of treatment, HRQL scores for the IFN regimen became significantly lower as compared to the IFN-free regimen (up to -11.2 decline on a 0-100 scale, p<0.0001). By the end of treatment, IFN-treated group experienced significant declines in most of HRQL scores (up to -13.2, p<0.02) while subjects on SOF/RBV had milder impairments (up to -5.4, all p<0.05 7/8 scales) (Figure); some of these impairments persisted up to post-treatment week 4. SVR-12 was associated with HRQL improvement regardless of regimen (up to +2.9, p<0.05). In multivariate analysis, IFN was the only consistent independent predictor of HRQL impairment during treatment (β: -4.1 to -10.7, p<0.009). Conclusions: Treatment of EA HCV patients with IFN is associated with significant HRQL impairment while IFN-free RBV+ regimens are associated with mild and reversible impairment. SVR-12 is associated with HRQL improvement regardless of regimen and country of origin.
DescriptionPoster presentation
Persistent Identifierhttp://hdl.handle.net/10722/262443
ISSN
2017 Impact Factor: 14.079
2015 SCImago Journal Rankings: 4.752

 

DC FieldValueLanguage
dc.contributor.authorYounossi, ZM-
dc.contributor.authorStepanova, M-
dc.contributor.authorHenry, L-
dc.contributor.authorHan, KH-
dc.contributor.authorAhn, SH-
dc.contributor.authorLim, YS-
dc.contributor.authorChuang, WL-
dc.contributor.authorKao, JH-
dc.contributor.authorNguyen, VAN K-
dc.contributor.authorLai, CL-
dc.contributor.authorYuen, RMF-
dc.contributor.authorChan, HYL-
dc.contributor.authorLai, W-
dc.date.accessioned2018-09-28T04:59:24Z-
dc.date.available2018-09-28T04:59:24Z-
dc.date.issued2017-
dc.identifier.citationThe 68th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2017, Washington DC, USA, 20-24 October 2017. In Hepatology, 2017, v. 66 n. Suppl. 1, p. 395A-396A, abstract no. 737-
dc.identifier.issn0270-9139-
dc.identifier.urihttp://hdl.handle.net/10722/262443-
dc.descriptionPoster presentation-
dc.description.abstractBackground: HCV cure leads to HRQL improvement. East Asian (EA) HCV patients have been underrepresented in HRQL studies. Aim: Assess HRQL in EA HCV patients treated with anti-HCV regimens. Methods: EA HCV patients completed Short Form-36 (SF-36) before, during and after treatment and HRQL scores were compared between regimens. Results: 686 EA HCV subjects were included [China: 56.7%, S. Korea: 18.8%, Taiwan: 12.7%, Vietnam: 7.3% and Hong Kong: 4.5%; Genotype (GT) 2: 40.8%, GT1: 29.6%, GT3: 18.4%, GT6: 11.2%; cirrhosis: 13.4%, treatment naïve: 66%]. Patients received pegylated interferon, sofosbuvir and ribavirin (IFN+SOF+RBV) for 12 weeks (n=155, GT 1 and 6) or SOF+RBV for 12-24 weeks (n=531, GT 1, 2, 3 and 6). The SVR-12 was 95.5% and 96.0% (p=0.76). Baseline HRQL scores were similar between treatment groups (all p>0.05). After 2 weeks of treatment, HRQL scores for the IFN regimen became significantly lower as compared to the IFN-free regimen (up to -11.2 decline on a 0-100 scale, p<0.0001). By the end of treatment, IFN-treated group experienced significant declines in most of HRQL scores (up to -13.2, p<0.02) while subjects on SOF/RBV had milder impairments (up to -5.4, all p<0.05 7/8 scales) (Figure); some of these impairments persisted up to post-treatment week 4. SVR-12 was associated with HRQL improvement regardless of regimen (up to +2.9, p<0.05). In multivariate analysis, IFN was the only consistent independent predictor of HRQL impairment during treatment (β: -4.1 to -10.7, p<0.009). Conclusions: Treatment of EA HCV patients with IFN is associated with significant HRQL impairment while IFN-free RBV+ regimens are associated with mild and reversible impairment. SVR-12 is associated with HRQL improvement regardless of regimen and country of origin.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/-
dc.relation.ispartofHepatology-
dc.relation.ispartofThe 68th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2017-
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.-
dc.titleHealth-Related Quality of Life (HRQL) in East Asian Patients with Hepatitis C Virus (HCV) Infection: The Impact of Treatment and Sustained Virologic Response (SVR)-
dc.typeConference_Paper-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityYuen, RMF=rp00479-
dc.identifier.hkuros292159-
dc.identifier.hkuros293857-
dc.identifier.volume66-
dc.identifier.issueSuppl. 1-
dc.identifier.spage395A-
dc.identifier.epage396A-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats